Please login to the form below

Not currently logged in
Email:
Password:

Former Merck Serono CEO Elmar Schnee joins board of Anecova

Benedict Hentsch of Bank Benedict Hentsch and former Novartis Animal Health CEO Hans-Beat Gürtle also join reproductive health company

Elmar ScheeSwiss technology company Anecova has appointed three new members to its board, including former Merck Serono CEO Elmar Schnee.

The other two new additions are Benedict Hentsch, chair of Bank Benedict Hentsch, and Hans-Beat Gürtler, managing director of private investors Varuma and a former CEO of Novartis Animal Health.

Martin Velasco, founder and chair of Anecova, which specialises in developing new technologies to assist artificial reproduction, said: “We are delighted to count on these three experienced international executives in our board of directors.

“They will bring a unique expertise from the industrial, financial, fertility and pharmaceutical businesses that will be instrumental for the future development of our company”.

Schnee joined Merck KGaA in 2003 as president of its French business, before being elected general partner and member of the executive board responsible for the company's global pharma activities.

During his time at Merck, he led the acquisition of Serono to become CEO of the merged company.

He left in 2011, and has served as chair and CEO of biopharma Cardiorentis since October, 2012.

Gürtler served as global CEO for Novartis Animal Health from 1990 to 2002, before joining Varuma. He is also vice chair of Basilea Pharmaceutica and Implenia.

Prior to founding Bank Benedict Hentsch, Hentsch was managing partner of Darier Hentsch & Cie until 2001.

31st May 2012

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Cogora

Cogora has been a leader in healthcare publishing for over 30 years and has become one of the leading full-service...

Latest intelligence

image 1
Redefining communications excellence
How to be heard in today’s multichannel, multistakeholder, multimedia world...
AZ Campus
AstraZeneca: building a new ‘open innovation’ pharma company
The construction of its new HQ has suffered some serious delays, but new R&D and commercial success are lifting AstraZeneca’s prospects...
Erik Nordkamp
In conversation with Pfizer’s Erik Nordkamp
Pfizer’s UK general manager talks to PME about the NHS at 70, the potential of pharma partnerships and some lessons from Europe...

Infographics